Skip to content
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Neurology · Secondary Progressive Multiple Sclerosis

How Is Secondary Progressive MS Diagnosed After RRMS?

At a Glance

Secondary progressive MS is diagnosed by tracking gradual, lasting decline in physical or cognitive function over several months, separate from relapses or other causes. Neurological exams, functional tests, symptom history, and MRI comparisons support the assessment, but no single test confirms SPMS.

There is no single blood test, MRI scan, or specific symptom that definitively diagnoses the transition from relapsing-remitting MS (RRMS) to secondary progressive MS (SPMS) [1][2]. Instead, a doctor diagnoses SPMS based on a longitudinal clinical assessment—meaning they observe your disease pattern over time [3][4]. They look for a gradual, sustained worsening of physical or cognitive disability over several months that is not simply the result of a recent relapse [1][5]. Because this change happens slowly, SPMS is often diagnosed retrospectively, after you and your doctor look back at your health history over the past 6 to 12 months [6][1].

Safety Note: Always contact your care team promptly if you experience sudden, severe neurologic symptoms (such as sudden weakness, vision loss, or confusion) or a fever. Do not wait to see if they form a pattern over months, as abrupt changes could indicate a severe relapse, an infection, or another medical emergency.

Recognizing the Pattern of Sustained Worsening

The core feature of SPMS is disability that accumulates independently of clinically apparent relapses [1][5]. In RRMS, you may experience a relapse followed by partial or complete recovery. In SPMS, you may notice a slow, persistent decline in your baseline abilities [7]. RRMS and SPMS exist on a continuum; there is no single day when a “switch” flips [8].

To confirm this shift, your neurologist will track changes in your function over multiple visits. They typically look for worsening that persists over several months (often 3 to 12 months, depending on the clinical framework being used) [4][9]. Crucially, they need to determine that this worsening is independent of a relapse. This does not mean you cannot have a relapse if you have SPMS. It simply means the doctor must confirm that your gradual decline is not just incomplete recovery from a recent relapse [1][10].

Because standard scales like the Expanded Disability Status Scale (EDSS)—which heavily weights walking ability—might miss subtle changes in other areas, doctors often use a combination of tools to measure progression [11]:

  • Timed 25-Foot Walk to objectively measure walking speed and mobility [11][12].
  • 9-Hole Peg Test to measure hand and arm dexterity [11][12].
  • Cognitive screening (such as the Symbol Digit Modalities Test, or SDMT) to track changes in processing speed and attention [13][12].

Self-reporting is also crucial. Telling your doctor about gradual, unrecovered changes in your walking, balance, muscle strength, fatigue, or processing speed can help your care team detect possible progression earlier [7][14].

Evaluating Other Contributors to Worsening

Before attributing a decline in function to SPMS, your care team will evaluate other factors that might be contributing to your symptoms [15][16]. A person can have SPMS alongside other health conditions, but it is important to address anything else that might be making your MS feel worse. Your doctor will consider:

  • Pseudorelapses: A temporary worsening of old MS symptoms triggered by a fever, infection (like a urinary tract infection), heat, or stress, rather than true disease progression.
  • Aging and Deconditioning: Natural age-related changes or a loss of fitness and muscle tone from decreased physical activity [15][16].
  • Comorbidities and other factors: Conditions like arthritis (orthopedic problems), sleep disorders, vascular disease, thyroid issues, anemia, or side effects from medications can mimic MS progression or worsen your overall function [15][17].
  • Incomplete Recovery: Lingering damage from a recent, severe relapse rather than a new progressive phase.

Active vs. Nonactive SPMS

A common misconception is that once MS becomes progressive, inflammation (relapses and new MRI lesions) completely stops. In reality, disease activity (inflammation) and disease progression (worsening baseline) are two separate dimensions [18]. Your doctor will describe your SPMS based on whether you are still experiencing active inflammation:

  • Active SPMS (Active with Progression): Your disability gradually worsens, but you also experience occasional clinical relapses or have new/enlarging spots on your MRI during the assessment period [18][19].
  • Nonactive SPMS (Nonactive with Progression): Your disability gradually worsens, and you have not had any recent relapses or new MRI activity during the assessment period [18][19].

Knowing whether your MS is active or nonactive helps your doctor recommend the best disease-modifying therapies, though rehabilitation, physical therapy, and symptom management remain vital for both types [18].

Why Isn’t There a Single Diagnostic Test?

You might wonder why a doctor can’t just order an MRI or blood test to see if you have SPMS. While MRIs are critical for monitoring MS, findings on an MRI (such as brain atrophy or slowly expanding lesions) overlap between different types of MS [4][20]. An MRI can help rule out other neurological conditions or identify if your disease is “active,” but it cannot pinpoint the exact moment your disease becomes progressive [4][2]. Similarly, while researchers are studying certain blood biomarkers, none are currently validated to make an early SPMS diagnosis [21][8].

Because there is no single test, an evaluation for SPMS typically involves:

  1. Reviewing your symptom history to check for subtle day-to-day changes [3].
  2. A neurological exam to objectively measure reflexes, strength, and coordination [3].
  3. Standardized functional tests (like the Timed 25-Foot Walk and cognitive screening) [11].
  4. Comparing recent MRIs to older ones to check for new disease activity [19].
  5. Evaluating for alternative causes like infections or other medical conditions [15].

Diagnosis remains fundamentally rooted in your personal clinical history and how your symptoms evolve over time [8][22].

Common questions in this guide

How is SPMS diagnosed after relapsing-remitting MS?
Doctors diagnose SPMS by reviewing how your symptoms and abilities have changed over time. They look for gradual, lasting worsening of function, often over several months, that is not explained only by a recent relapse or another health problem. There is no single blood test or MRI that confirms the transition.
How long must symptoms worsen before SPMS can be recognized?
Clinicians often look for sustained worsening for about 3 to 12 months, although the timeframe depends on the clinical framework and the individual case. Because progression is gradual, the diagnosis may be made retrospectively by comparing function over the previous 6 to 12 months.
What tests are used to check for progression to SPMS?
A neurologist may use your symptom history, a neurological exam, the Expanded Disability Status Scale, the Timed 25-Foot Walk, the 9-Hole Peg Test, and cognitive screening such as the Symbol Digit Modalities Test. MRI scans can show new disease activity and help rule out other conditions, but an MRI cannot diagnose SPMS by itself.
How can doctors tell SPMS progression from a relapse or pseudorelapse?
Doctors check whether the decline is a slow, persistent change in your usual abilities rather than a sudden episode followed by recovery. Fever, infection, heat, stress, incomplete recovery, aging, deconditioning, sleep problems, other illnesses, or medication effects can temporarily worsen symptoms and must also be considered.
What does active or nonactive SPMS mean?
Active SPMS means disability is worsening and there are also recent relapses or new or enlarging MRI lesions. Nonactive SPMS means disability is worsening without recent relapses or new MRI activity. These labels help guide treatment discussions, while rehabilitation and symptom management may be useful in either pattern.

Get notified when new evidence is published on relapsing-remitting multiple sclerosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (22)
  1. 1

    Secondary Progressive Multiple Sclerosis: New Insights.

    Cree BAC, Arnold DL, Chataway J, et al.

    Neurology 2021; (97(8)):378-388 doi:10.1212/WNL.0000000000012323.

    PMID: 34088878
  2. 2

    Secondary progressive multiple sclerosis - from neuropathology to definition and effective treatment.

    Adamczyk-Sowa M, Adamczyk B, Kułakowska A, et al.

    Neurologia i neurochirurgia polska 2020; (54(5)):384-398 doi:10.5603/PJNNS.a2020.0082.

    PMID: 33058113
  3. 3

    Clinical and Paraclinical Biomarkers and the Hitches to Assess Conversion to Secondary Progressive Multiple Sclerosis: A Systematic Review.

    Krajnc N, Bsteh G, Berger T

    Frontiers in neurology 2021; (12()):666868 doi:10.3389/fneur.2021.666868.

    PMID: 34512500
  4. 4

    Secondary progressive multiple sclerosis: A national consensus paper on diagnostic criteria.

    Ciron J, Gueguen A, Al Khedr A, et al.

    Revue neurologique 2022; (178(10)):1098-1104 doi:10.1016/j.neurol.2022.07.004.

    PMID: 36180289
  5. 5

    Secondary Progressive Multiple Sclerosis: Definition and Measurement.

    Plantone D, De Angelis F, Doshi A, Chataway J

    CNS drugs 2016; (30(6)):517-26 doi:10.1007/s40263-016-0340-9.

    PMID: 27166830
  6. 6

    [New tools for early detection of multiple sclerosis progression: MSProDiscuss questionnaire].

    Volkov AI, Popova EV

    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 2020; (120(7. Vyp. 2)):43-47 doi:10.17116/jnevro202012007243.

    PMID: 32844629
  7. 7

    A mixed methods approach towards understanding key disease characteristics associated with the progression from RRMS to SPMS: Physicians' and patients' views.

    Ziemssen T, Tolley C, Bennett B, et al.

    Multiple sclerosis and related disorders 2020; (38()):101861 doi:10.1016/j.msard.2019.101861.

    PMID: 31865132
  8. 8

    Should We Use Clinical Tools to Identify Disease Progression?

    Inojosa H, Proschmann U, Akgün K, Ziemssen T

    Frontiers in neurology 2020; (11()):628542 doi:10.3389/fneur.2020.628542.

    PMID: 33551982
  9. 9

    Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis.

    Müller J, Sharmin S, Lorscheider J, et al.

    JAMA neurology 2025; (82(6)):614-625 doi:10.1001/jamaneurol.2025.0495.

    PMID: 40227706
  10. 10

    Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis.

    Lizak N, Malpas CB, Sharmin S, et al.

    JAMA neurology 2020; (77(11)):1398-1407 doi:10.1001/jamaneurol.2020.2453.

    PMID: 32716480
  11. 11

    The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis.

    Cadavid D, Cohen JA, Freedman MS, et al.

    Multiple sclerosis (Houndmills, Basingstoke, England) 2017; (23(1)):94-105 doi:10.1177/1352458516638941.

    PMID: 27003945
  12. 12

    [Neuropsychological and MRI diagnostics in secondary progressive multiple sclerosis].

    Penner IK, Gass A, Schreiber H, Wattjes MP

    Der Nervenarzt 2021; (92(12)):1293-1301 doi:10.1007/s00115-021-01118-9.

    PMID: 33891150
  13. 13

    Consensus on early detection of disease progression in patients with multiple sclerosis.

    Meca-Lallana JE, Casanova B, Rodríguez-Antigüedad A, et al.

    Frontiers in neurology 2022; (13()):931014 doi:10.3389/fneur.2022.931014.

    PMID: 35968319
  14. 14

    Patient-reported gradual worsening reveals progression beyond MS subtypes.

    Guo J, Olsson T, Alfredsson L, Hedström AK

    Journal of neurology 2026; (273(2)):117.

    PMID: 41652249
  15. 15

    Challenges and Innovation for Diagnosing and Treatment of Secondary Progressive Multiple Sclerosis.

    Uawithya E, Mytych JS, Muwenda I, et al.

    International journal of molecular sciences 2026; (27(10)) doi:10.3390/ijms27104558.

    PMID: 42196536
  16. 16

    Progression independent of relapsing biology in multiple sclerosis: a real-word study.

    Yong HYF, Camara-Lemarroy C

    Frontiers in neurology 2025; (16()):1595929 doi:10.3389/fneur.2025.1595929.

    PMID: 40510203
  17. 17

    Progressive Multiple Sclerosis.

    Amezcua L

    Continuum (Minneapolis, Minn.) 2022; (28(4)):1083-1103 doi:10.1212/CON.0000000000001157.

    PMID: 35938658
  18. 18

    [Disease-modifying treatment of secondary progressive multiple sclerosis].

    Hoffmann O, Gold R

    Der Nervenarzt 2021; (92(10)):1052-1060 doi:10.1007/s00115-021-01080-6.

    PMID: 33656569
  19. 19

    Characteristics of secondary progressive multiple sclerosis: Disease activity and provision of care in Germany - A registry-based/multicentric cohort study.

    Frahm N, Ellenberger D, Fneish F, et al.

    Multiple sclerosis and related disorders 2021; (56()):103281 doi:10.1016/j.msard.2021.103281.

    PMID: 34624644
  20. 20

    Diagnosis of Progressive Multiple Sclerosis From the Imaging Perspective: A Review.

    Filippi M, Preziosa P, Barkhof F, et al.

    JAMA neurology 2021; (78(3)):351-364 doi:10.1001/jamaneurol.2020.4689.

    PMID: 33315071
  21. 21

    Early diagnosis of secondary progressive multiple sclerosis: focus on fluid and neurophysiological biomarkers.

    Ferrazzano G, Crisafulli SG, Baione V, et al.

    Journal of neurology 2021; (268(10)):3626-3645 doi:10.1007/s00415-020-09964-4.

    PMID: 32504180
  22. 22

    Secondary Progressive Multiple Sclerosis: A Review of Clinical Characteristics, Definition, Prognostic Tools, and Disease-Modifying Therapies.

    Ziemssen T, Bhan V, Chataway J, et al.

    Neurology(R) neuroimmunology & neuroinflammation 2023; (10(1)) doi:10.1212/NXI.0000000000200064.

    PMID: 36414428

This page is for informational purposes only and does not constitute medical advice about a possible transition to SPMS. Discuss changes in symptoms, testing, and treatment with your neurologist, and seek prompt care for sudden or severe symptoms.